ClinicaliQ Trial Snapshot
- BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT — Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT06059638.
- What is being tested: A novel atrioventricular interval modulation (AVIM) algorithm integrated into dual-chamber pacemakers to evaluate its safety and effectiveness as a potential blood pressure treatment strategy.
- Patient eligibility overview: The trial includes patients requiring dual-chamber pacemaker implantation across multiple countries in a prospective, randomized, double-blind design, with specific eligibility criteria related to cardiac and blood pressure status (detailed criteria not specified in summary).
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
A prospective, multinational, randomized, double-blind, clinical trial evaluating the safety and effectiveness of a novel atrioventricular interval modulation (AVIM) algorithm downloaded into a dual-chamber Medtronic Astra/Azure pacemaker.
Eligibility Snapshot
- :
- Patient has or is indicated for a dual-chamber pacemaker. Visit 1 can be performed within 30 days prior to a planned implant of a Medtronic Astra/Azure dual-chamber pacemaker system or at any time thereafter 2. On a stable antihypertension treatment regimen with at least 1 class of antihypertensive drug 3. Office SBP ≥135 mmHg and
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.